Impact of Long-Term Oral Beta-Blocker Therapy on Patients with Myocardial Infarction

Study Overview

A recent meta-analysis published in The Lancet has shown that long-term oral beta-blocker therapy, including medications such as bisoprolol, metoprolol, and carvedilol, can significantly reduce the risk of all-cause death, new myocardial infarction, or heart failure by 25% in patients who have experienced a myocardial infarction (MI) and have mildly reduced left ventricular ejection fraction (LVEF) of 40-49%. This analysis reviewed data from four randomized controlled trials: REBOOT, BETAMI, DANBLOCK, and CAPITAL-RCT, involving 1,885 patients hospitalized for acute MI with mildly reduced LVEF.

Study Design and Patient Demographics

Within the study, 991 patients were assigned to receive beta-blockers, while 894 were placed in a control group without beta-blocker therapy. Specifically, bisoprolol was administered to 430 patients (44%), metoprolol to 485 patients (49%), and carvedilol to 46 patients (5%).

Key Findings of the Meta-Analysis

The meta-analysis revealed several important outcomes related to the efficacy of beta-blocker therapy:

– **Composite Endpoint Reduction**: The use of beta-blockers led to a 25% reduction in the composite endpoint of all-cause death, new myocardial infarction, or heart failure, with event rates of 11% in the beta-blocker group versus 14% in the control group (HR 0.75, 95% CI 0.58-0.97; p=0.031).

– **All-Cause Death**: Beta-blocker therapy was associated with a 22% reduction in all-cause mortality, with rates of 6% in the beta-blocker group compared to 8% in the control group (HR 0.78, 95% CI 0.55-1.11; p=0.169).

– **Cardiac Death**: There was a notable 45% reduction in cardiac deaths, occurring in 2% of the beta-blocker group versus 3% in the control group (HR 0.55, 95% CI 0.28-1.06; p=0.076).

– **New Myocardial Infarction**: The occurrence of new myocardial infarctions was reduced by 23%, with 4% in the beta-blocker group and 5% in the control group (HR 0.77, 95% CI 0.50-1.18; p=0.230).

– **Heart Failure**: Beta-blocker therapy reduced the incidence of heart failure by 29%, with 3% in the beta-blocker group compared to 4% in the control group (HR 0.71, 95% CI 0.44-1.14; p=0.152).

Temporal Benefits of Beta-Blocker Therapy

The therapeutic benefits of beta-blocker therapy began to manifest approximately three months post-initiation and continued to accumulate over the median follow-up period of 3.5 years (IQR 2.3-4.5). This sustained separation of survival curves indicates that the clinical advantages are primarily derived from long-term therapy rather than immediate protective effects.

Consistency Across Trials

The benefits of beta-blocker therapy were consistently observed across all four trials included in the analysis, showing no evidence of heterogeneity (Cochran’s Q test p=0.95, I²=0%). Furthermore, there was no significant variation in treatment effects based on sex, type of myocardial infarction, LVEF category, dosage, or geographical location, underscoring the universal applicability of these findings across diverse healthcare settings.

Safety Profile of Beta-Blocker Therapy

Safety analyses indicated no significant increase in adverse events associated with beta-blocker therapy, reinforcing the treatment’s safety profile.

Expert Perspectives on the Findings

Experts have noted that patients post-MI with mildly reduced LVEF (40–49%) have previously existed in a therapeutic grey zone. The findings of this meta-analysis may support treating this patient group similarly to those with heart failure with reduced ejection fraction (HFrEF) when considering long-term beta-blocker therapy. Dr. Sunip Banerjee, Sr. Consultant Interventional Cardiologist & Chairman at Kolkata Heart Lung Centre, emphasized the importance of evaluating the implications for treatment strategies in this demographic.